Stabilitech secures £3.3 million Equity Funding

~ Financing to Accelerate Vaccine and Biopharmaceutical Stabilisation Technology ~

London, UK, 12 March 2009. Stabilitech Ltd, a private company developing proprietary thermal stabilisation technologies for the vaccine and biopharmaceutical markets, is pleased to announce today that it has successfully raised £3.3 million of equity finance from new and existing investors, including business angels and high net worth individuals. The funds will be used over the next two years to accelerate the development and commercialisation of its proprietary technology platform for stabilising vaccines, biopharmaceuticals and other biological products and to explore other potential applications for the technology such as diagnostics.

Highlights:

• Successful completion of £3.3 million of equity financing from new and existing investors
• The funds will be used to generate further data packages for marketing to potential partners in the vaccine, biopharmaceutical and other biologicals markets
• Two feasibility studies already underway with potential partners, one of which is a major pharmaceutical company

Stabilitech, a private company based at the Imperial College Incubator, has a cutting edge proprietary thermal stabilisation technology platform that enables vaccines and biopharmaceuticals to be stored at a wide range of temperatures. The technology has
applications for early stage development products as well as for new formulations of existing products to form next generation medicines with competitive advantage. Currently, to ensure
potency, vaccines and biopharmaceuticals require storage and transport under strictly controlled temperatures in a cold chain.

Stabilitech’s technology platform will enable the long term stable storage of these products over a wide range of temperatures, protecting against both heat and freeze damage. The technology has been successfully applied to live viral vaccines (a particularly challenging target) including both enveloped and non-enveloped viruses, inactivated viruses and sub-unit vaccines as well as to antibodies, peptides, enzymes, growth factors and other proteins.

The funds raised will be used to generate further data packages that will assist the Company to build partnerships with companies in the vaccine, biopharmaceutical and other biologicals markets and to explore additional potential applications, such as diagnostics. The Company is already working with vaccine manufacturers and global health organisations to help commercialise its proprietary technologies and currently has two feasibility studies underway,
one with a large pharmaceutical company and the other with a diagnostics company. Upon the completion of such feasibility studies, the Company aims to license its technology platform
to larger organisations for development and commercialisation.

This financing brings the total funds raised by the company to date to £5.2 million.

Dr Barbara Domayne-Hayman, Stabilitech’s CEO, said: “We are very pleased to have completed this fund-raising given the current economic climate and are delighted to have actually exceeded our original target amount. We see this as an endorsement of the high
potential of our technology, and we now have the opportunity to accelerate development and commercialisation in both vaccines and biopharmaceuticals, as well as to explore other potential applications such as diagnostics.”

-ENDS